Compare SMID & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SMID | IPHA |
|---|---|---|
| Founded | 1960 | 1999 |
| Country | United States | France |
| Employees | N/A | 163 |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.1M | 141.7M |
| IPO Year | 1996 | N/A |
| Metric | SMID | IPHA |
|---|---|---|
| Price | $33.18 | $1.42 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $5.75 |
| AVG Volume (30 Days) | 7.0K | ★ 23.7K |
| Earning Date | 04-14-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 62.76 | N/A |
| EPS | ★ 2.36 | N/A |
| Revenue | ★ $93,446,000.00 | N/A |
| Revenue This Year | N/A | $180.36 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $14.19 | ★ N/A |
| Revenue Growth | ★ 19.03 | N/A |
| 52 Week Low | $25.60 | $1.18 |
| 52 Week High | $43.62 | $2.63 |
| Indicator | SMID | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 57.33 | 47.01 |
| Support Level | $32.79 | $1.18 |
| Resistance Level | $33.86 | $1.80 |
| Average True Range (ATR) | 1.61 | 0.08 |
| MACD | 0.56 | 0.01 |
| Stochastic Oscillator | 93.75 | 27.91 |
Smith-Midland Corp through its subsidiaries invents, develops, manufactures, markets, sells, and installs precast concrete products for primary use in the construction, highway, utilities, and farming industries. The firm's customers are general contractors and federal, state, and local transportation authorities. Its products include Slenderwall, JJhooks, Softsound, Sierra Wall and Easi set. A substantial portion of the company's business is derived from local, state, and federal building projects. The company generates revenues predominantly from the sale, leasing, licensing, shipping, and installation of precast concrete products for the construction, utility, and farming industries.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. The company's approach includes therapeutic modalities such as monoclonal antibodies, multispecific NK cell engagers through its ANKET platform, and antibody-drug conjugates (ADC). Its portfolio includes lacutamab, which is being studied for cutaneous T-cell lymphomas and peripheral T-cell lymphomas, and monalizumab, which is being developed in collaboration with AstraZeneca for non-small cell lung cancer. The company's revenue mainly consists of revenues from collaboration and licensing agreements and government financing for research expenditure in the form of research tax credits, as well as other grants.